Likelihood of Approval and Phase Transition Success Rate Model – Lorlatinib in Neuroblastoma
Powered by ![]()
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Lorlatinib in Neuroblastoma report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.


Lorlatinib in Neuroblastoma Drug Details:
Lorlatinib (Lorviqua / Lorbrena/ Lorlak) is a kinase inhibitor act as anti-neoplastic agent. It is formulated as tablets, coated tablets, film coated tablets for oral route of administration. It is indicated for the treatment of unresectable advanced or recurrent ALK fusion gene positive non-small cell lung cancer unresectable advanced or recurrent fusion gene positive, resistance or intolerance to ALK tyrosine kinase inhibitors, and also for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease, or alectinib as the first ALK inhibitor therapy for metastatic disease, or ceritinib as the first ALK inhibitor therapy for metastatic disease. Lorbrena is indicated as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).Lorlatinib (PF-06463922) is under development for the treatment of metastatic non-small cell lung cancer, anaplastic large cell lymphoma, neuroblastoma, high-grade (HGG), including diffuse intrinsic pontine gliomas (DIPG) anaplastic astrocytoma, glioblastoma. The drug candidate is a new molecular entity (NME). The drug candidate is administered orally as a tablet. It is an ATP competitive small molecule inhibitor of anaplastic lymphoma kinase (ALK) and ROS1. It was under development for the treatment of lymphoma and glioblastoma multiforme.
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
| Quick View – Lorlatinib LOA Data | |||||
| Report Segments |
|
||||
| Drug Name |
|
||||
| Administration Pathway |
|
||||
| Therapeutic Areas |
|
||||
| Key Manufacturers |
|
||||
| Drug Development Status |
|
||||
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports